Keybank National Association OH Sells 674 Shares of NeoGenomics, Inc. (NASDAQ:NEO) – Watch List News
Several other hedge funds have also recently modified their holdings of NEO. Oak Ridge Investments LLC raised its holdings in shares of NeoGenomics by 751.8% in the 1st quarter. Oak Ridge Investments LLC now owns 2,723,474 shares of the medical research company’s stock valued at $131,353,000 after purchasing an additional 2,403,756 shares during the period. Norges Bank bought a new stake in shares of NeoGenomics in the 4th quarter valued at about $50,808,000. BlackRock Inc. raised its holdings in shares of NeoGenomics by 5.3% in the 4th quarter. BlackRock Inc. now owns 17,246,570 shares of the medical research company’s stock valued at $928,557,000 after purchasing an additional 861,490 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of NeoGenomics in the 4th quarter valued at about $32,304,000. Finally, Compagnie Lombard Odier SCmA bought a new stake in shares of NeoGenomics in the 1st quarter valued at about $17,411,000. 90.82% of the stock is currently owned by institutional investors.
In other news, insider Robert J. Shovlin sold 130,604 shares of the company’s stock in a transaction that occurred on Tuesday, May 25th. The shares were sold at an average price of $39.31, for a total transaction of $5,134,043.24. Following the completion of the sale, the insider now owns 249,914 shares of the company’s stock, valued at approximately $9,824,119.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.70% of the company’s stock.
Shares of NASDAQ:NEO opened at $41.03 on Friday. The company’s 50 day moving average price is $44.64 and its two-hundred day moving average price is $49.34. NeoGenomics, Inc. has a 12-month low of $25.19 and a 12-month high of $61.57. The firm has a market cap of $4.84 billion, a PE ratio of -512.88 and a beta of 0.68. The company has a quick ratio of 13.60, a current ratio of 13.91 and a debt-to-equity ratio of 0.63.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, May 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.05). NeoGenomics had a positive return on equity of 0.83% and a negative net margin of 2.42%. The business had revenue of $115.30 million for the quarter, compared to analyst estimates of $112.17 million. During the same quarter in the previous year, the company earned ($0.07) EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, research analysts expect that NeoGenomics, Inc. will post -0.35 EPS for the current year.
NEO has been the topic of a number of research reports. Zacks Investment Research lowered shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 28th. Craig Hallum upped their price target on shares of NeoGenomics from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 25th. Morgan Stanley upped their price target on shares of NeoGenomics from $46.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, March 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of NeoGenomics in a research note on Friday, April 16th. Finally, Raymond James reiterated a “market perform” rating on shares of NeoGenomics in a research note on Wednesday, March 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. NeoGenomics presently has an average rating of “Buy” and an average price target of $50.05.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Featured Story: Terms to Better Understand Call Options
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source